Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months ...

DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain New York, USA, April 24, 2023 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain The prevalence...

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) --...

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...

Global Waldenstrom Macroglobulinemia (WM) Market Spotlight Report 2021: Bristol Myers Squibb, Johnson & Johnson, and Takeda Lead Industry Sponsors with the Highest Overall Number of Clinical Trials Dublin, June 08, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Waldenstrom Macroglobulinemia (WM)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...